Amylyx Pharmaceuticals annual free cash flow
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Free Cash Flow (FCF) History (AMLX)
Amylyx Pharmaceuticals reported −$123.5M in free cash flow for fiscal 2025, an increase of $44.3M from the previous fiscal year.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$123.5M | $44.3M | — | — |
| 2024 | 2024-12-31 | −$167.8M | −$178.5M | — | −192.06% |
| 2023 | 2023-12-31 | $10.7M | $193.1M | — | +2.80% |
| 2022 | 2022-12-31 | −$182.4M | −$107.2M | — | −820.50% |
| 2021 | 2021-12-31 | −$75.2M | — | — | −26369.12% |
Amylyx Pharmaceuticals quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$28.0M | $31.0M | — | — |
| Q3 2025 | 2025-09-30 | −$30.4M | $11.2M | — | — |
| Q2 2025 | 2025-06-30 | −$25.3M | $41.4M | — | — |
| Q1 2025 | 2025-03-31 | −$39.8M | −$39.3M | — | — |
| Q4 2024 | 2024-12-31 | −$59.0M | −$72.2M | — | — |
| Q3 2024 | 2024-09-30 | −$41.6M | −$36.1M | — | −9997.36% |
| Q2 2024 | 2024-06-30 | −$66.7M | −$75.0M | — | — |
| Q1 2024 | 2024-03-31 | −$556,000 | $4.8M | — | −0.63% |
| Q4 2023 | 2023-12-31 | $13.2M | $63.5M | — | +12.17% |
| Q3 2023 | 2023-09-30 | −$5.5M | $38.0M | — | −5.38% |
| Q2 2023 | 2023-06-30 | $8.3M | $55.9M | — | +8.48% |
| Q1 2023 | 2023-03-31 | −$5.3M | $35.7M | — | −7.45% |
| Q4 2022 | 2022-12-31 | −$50.3M | −$21.9M | — | — |
| Q3 2022 | 2022-09-30 | −$43.5M | −$22.5M | — | −12619.42% |
| Q2 2022 | 2022-06-30 | −$47.6M | −$34.5M | — | — |
| Q1 2022 | 2022-03-31 | −$41.0M | −$28.3M | — | — |
| Q4 2021 | 2021-12-31 | −$28.4M | — | — | — |
| Q3 2021 | 2021-09-30 | −$21.0M | — | — | −7374.74% |
| Q2 2021 | 2021-06-30 | −$13.0M | — | — | — |
| Q1 2021 | 2021-03-31 | −$12.7M | — | — | — |
Amylyx Pharmaceuticals free cash flow growth trends
Amylyx Pharmaceuticals's latest reported quarter, Q4 2025, generated −$28.0M in free cash flow, an increase of $31.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Amylyx Pharmaceuticals filings at SEC.gov ↗